Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Phase 1PaxalisibPositive

AI Analysis

Summary

Kazia Therapeutics announced that Sovargen Co. has dosed the first patient in a Phase 1b/2a trial of Paxalisib for rare seizure disorders, expanding the drug's development beyond oncology and triggering a $2 million payment to Kazia.

Clinical Trial Data

Phase

1b/2a

Outcome Details

First patient dosed in Phase 1b/2a trial

Importance:6/10

Sentiment:

0.70

Phase_1b/2a_initiationrare_seizure_disordersmilestone_paymentclinical_expansiononcology_companypaxalisib

Related Companies

$KZIA

Read the original article

Published by PR Newswire Biotech on September 22, 2026 11:30 AM

Read Original